scholarly journals The cost of childhood atopic dermatitis in a multi‐ethnic Asian population: a cost‐of‐illness study

2019 ◽  
Vol 182 (5) ◽  
pp. 1245-1252 ◽  
Author(s):  
M. Olsson ◽  
R. Bajpai ◽  
L.W.Y. Wee ◽  
Y.W. Yew ◽  
M.J.A. Koh ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Cost Of Illness ◽  
Asian Population ◽  
Illness Study ◽  
The Cost ◽  
Cost Of Illness Study

scholarly journals Cost of illness study for adult atopic dermatitis in Japan: A cross‐sectional Web‐based survey

2020 ◽  
Vol 47 (7) ◽  
pp. 689-698 ◽  
Author(s):  
Hiroyuki Murota ◽  
Sachie Inoue ◽  
Kazufumi Yoshida ◽  
Atsushi Ishimoto
Keyword(s):  
Atopic Dermatitis ◽  
Cost Of Illness ◽  
Cross Sectional ◽  
Web Based ◽  
Illness Study ◽  
Cost Of Illness Study

The economic cost of schizophrenia in Ireland: a cost of illness study

2008 ◽  
Vol 25 (3) ◽  
pp. 80-87 ◽  
Author(s):  
Caragh Behan ◽  
Brendan Kennelly ◽  
Eadbhard O'Callaghan
Keyword(s):  
Informal Care ◽  
Cost Of Illness ◽  
Indirect Costs ◽  
Economic Cost ◽  
Premature Mortality ◽  
Illness Study ◽  
Lost Productivity ◽  
Human Cost ◽  
The Cost ◽  
Cost Of Illness Study

AbstractObjectives: Although there are many published reports about the human cost of schizophrenia, there are far fewer estimates of its economic cost, particularly in Ireland. The aim of this study was to provide a prevalence-based estimate of the costs associated with schizophrenia in Ireland during 2006.Method: Using standard Cost of Illness (COI) procedures we compiled data from many sources including the Health Research Board, the Department of Health and Children and other government publications. Costs relating to health and social care, informal care, lost productivity, premature mortality and other public expenditures were included. Where national data were unavailable, we used bottom-up data from a geographically defined catchment area study and, in some instances, costs from two catchment areas were averaged. We did not measure human or intangible costs.Results: The estimated total cost of schizophrenia was €460.6 million in 2006. The direct cost of care was €117.5 million and the burden of indirect costs was €343 million. The cost of lost productivity due to unemployment, absence from work and premature mortality was €277 million. Within indirect costs, the expenditure on informal care borne by families was €43.8 million.Conclusions: Schizophrenia is not a very common condition but is an expensive one. This is attributable to its young age at onset, relatively low mortality rate and high severity particularly in terms of its impact on future employment. Measures to improve outcomes coupled with measures to improve employment such as supported employment strategies may impact significantly on the cost of schizophrenia. The study is limited because the national unit costs of many variables are not directly available and these Irish data are likely to be an underestimate. However, the results are comparable with a 2005 cost of illness study UK study.

scholarly journals Cutaneous melanoma: cost of illness under Brazilian health system perspectives

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Cassia Rita Pereira da Veiga ◽  
Claudimar Pereira da Veiga ◽  
Alceu Souza ◽  
Alberto Julius Alves Wainstein ◽  
Andreia Cristina de Melo ◽  
...  
Keyword(s):  
Health System ◽  
Cost Of Illness ◽  
Value Chain ◽  
Advanced Disease ◽  
Early Stage ◽  
Decision Makers ◽  
Health Value ◽  
Illness Study ◽  
The Cost ◽  
Cost Of Illness Study

Abstract Background The landscape of cutaneous melanoma (CM) diagnosis, staging, prognosis, and treatment has undergone fundamental changes in the past decade. While the benefits of new health resources are recognized, there is a distinct lack of accurate cost-of-illness information to aid healthcare decision makers. Methods The cost-of-illness study for CM was conducted from the perspective of two health systems in Brazil: the public health system (Unified Health System, SUS) and the private health system (Health Management Organization, HMO). The study considered the direct medical cost in a bottom-up analysis, using melanoma incidence, knowledge of the disease’s progression, and the overall survival rates. The executional costs for the complete healthcare delivery cycle were investigated considering different disease stages and possible clinical course variations. The structural cost was assessed qualitatively considering the health value chain in Brazil. Results CM represents a critical financial burden in Brazil, and the cost of illness varied according to the health system and by stage at diagnosis. HMO patient costs are approximately 10-fold and 90-fold more than a SUS patient in the early-stage and advanced disease, respectively. Overall, spending on advanced disease patients can be up to 34-fold (SUS) or 270-fold (HMO) higher than that required for the early-stage disease. Given the massive amount of resources spent by the SUS and HMO, significant efforts must be made to improve the health value chain to deliver the right mix of medical care goods and services using available resources. Conclusion The cost-of-illness study for CM has the potential to inform policymakers and decision-makers regarding the economic burden that melanoma impose on a society in terms of the use of health care services, assisting them in making projections of future health care costs and resource allocation decisions. We believe that cost-of-illness analysis from a strategic perspective could be of help in assessing executional costs and be used to support the change in structural costs required for long-term strategies related to the health value chain.

The cost of pressure ulcer prevention and treatment in hospitals and nursing homes in Flanders: A cost-of-illness study

2015 ◽  
Vol 52 (7) ◽  
pp. 1166-1179 ◽  
Author(s):  
Liesbet Demarré ◽  
Sofie Verhaeghe ◽  
Lieven Annemans ◽  
Ann Van Hecke ◽  
Maria Grypdonck ◽  
...  
Keyword(s):  
Nursing Homes ◽  
Pressure Ulcer ◽  
Cost Of Illness ◽  
Pressure Ulcer Prevention ◽  
Prevention And Treatment ◽  
Illness Study ◽  
The Cost ◽  
Cost Of Illness Study ◽  
Ulcer Prevention

scholarly journals Snakebite envenomation in the Brazilian Amazon: a cost-of-illness study

2020 ◽  
Vol 114 (9) ◽  
pp. 642-649 ◽  
Author(s):  
Samara Freire Valente Magalhães ◽  
Henry Maia Peixoto ◽  
Jacqueline de Almeida Gonçalves Sachett ◽  
Sâmella S Oliveira ◽  
Eliane Campos Alves ◽  
...  
Keyword(s):  
Health System ◽  
Cost Of Illness ◽  
Premature Death ◽  
Brazilian Amazon ◽  
System Perspective ◽  
Illness Study ◽  
Absence From Work ◽  
The Cost ◽  
Cost Of Illness Study ◽  
Health System Perspective

Abstract Background Snakebites account for significant morbidity and mortality. Their occurrence in the Brazilian Amazon warrants an analysis that will enable better understanding of their economic impact and thus contribute to their management and prevention. This study aimed to estimate the cost of snakebite envenomation in the Brazilian Amazon in 2015. Methods We conducted a cost-of-illness study of snakebite in the Brazilian Amazon in 2015 based on official surveillance data to estimate burden from a societal, patient and public health system perspective. Direct medical costs were estimated via a top-down approach. Loss of productivity was estimated by a human capital approach. Results The study included 11 503 cases and 56 deaths. The estimated cost to the health system was US$3.115.861,28. The estimated cost due to premature death caused by snakebite was US$3031 300.38. The cost attributed to the loss of productivity due to absence from work was US$1539 518.62. The estimated cost from the patient's perspective was US$268 914.18. Therefore the total cost of snakebite in the Brazilian Amazon was estimated to be almost than US$8 million in 2015. Conclusions The economic burden of snakebite in Brazilian Amazon is notably high. Snakebites cause loss of productivity through inpatient treatment or deaths.

DIRECT COSTS OF TYPE 2 DIABETES: A BRAZILIAN COST-OF-ILLNESS STUDY

2018 ◽  
Vol 34 (2) ◽  
pp. 180-188 ◽  
Author(s):  
Ricardo Saad Henriques ◽  
Laiza Maria Steimbach ◽  
Deise Regina Baptista ◽  
Luana Lenzi ◽  
Fernanda S. Tonin ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cost Of Illness ◽  
Public Hospital ◽  
Direct Costs ◽  
Median Cost ◽  
United States Dollar ◽  
Illness Study ◽  
The Cost ◽  
Cost Of Illness Study

Objectives:The aim of this study was to evaluate the direct costs of type 2 diabetes mellitus patients treated in a Brazilian public hospital.Methods:This was an exploratory retrospective cost-of-illness study with quantitative approach, using medical records of patients treated in a public hospital (2012–14), with at least one consultation over a period of 12 months. Data on patient's profile, exams, number of consultations, medications, hospitalizations, and comorbidities were collected. The cost per patient per year (pppy) was calculated as well as the costs related to glycated hemoglobin (HbA1c) values, using thresholds of 7 and 8 percent.Results:Data of 726 patients were collected with mean age of 62 ± 11 years (68.3 percent female). A total of 67.1 percent presented HbA1c > 7 percent and 44.9 percent > 8 percent. The median cost of diabetes was United States dollar (USD) 197 pppy. The median costs of medication were USD 152.49 pppy, while costs of exams and consultations were USD 40.57 pppy and 8.70 pppy, respectively. Thirty-eight patients (4 percent) were hospitalized and presented a median cost of 3,656 per patient per hospitalization with a cost equivalent to 53.1 percent of total expenses. Total costs of patients with HbA1c ≤ 7 percent were lower for this group and also costs of medications and consultations, whereas for patients with HbA1c ≤ 8 percent, only total costs and costs of medications were lower when compared with HbA1c > 8 percent patients.Conclusions:Medications and hospitalizations were the major contributor of diabetes expenses. Preventing T2DM, or reducing its complications through adequate control, may help avoid the substantial costs related to this disease.

scholarly journals Healthcare Expenditures Associated with Heart Failure in Saudi Arabia: A Cost of Illness Study

Healthcare ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 988
Author(s):  
Ahmed Alghamdi ◽  
Eman Algarni ◽  
Bander Balkhi ◽  
Abdulaziz Altowaijri ◽  
Abdulaziz Alhossan
Keyword(s):  
Heart Failure ◽  
Saudi Arabia ◽  
Cost Of Illness ◽  
Economic Burden ◽  
Indirect Costs ◽  
Health Care Expenditures ◽  
Decision Makers ◽  
Hospitalization Costs ◽  
Illness Study ◽  
The Cost

Heart failure (HF) is considered to be a global health problem that generates a significant economic burden. Despite the growing prevalence in Saudi Arabia, the economic burden of HF is not well studied. The aim of this study was to estimate the health care expenditures associated with HF in Saudi Arabia from a social perspective. We conducted a multicenter cost of illness (COI) study in two large governmental centers in Riyadh, Saudi Arabia using 369 HF patients. A COI model was developed in order to estimate the direct medical costs associated with HF. The indirect costs of HF were estimated based on a human capital approach. Descriptive and inferential statistics were analyzed. The direct medical cost per HF patient was $9563. Hospitalization costs were the major driver in total spending, followed by medication and diagnostics costs. The cost significantly increased in line with the disease progression, ranging from $3671 in class I to $16,447 in class IV. The indirect costs per working HF patient were $4628 due to absenteeism, and $6388 due to presenteeism. The economic burden of HF is significantly high in Saudi Arabia. Decision makers need to focus on allocating resources towards strategies that prevent frequent hospitalizations and improve HF management and patient outcomes in order to lower the growing economic burden.

scholarly journals Burden of Congenital Hyperinsulinism In The United Kingdom: A Cost of Illness Study

2016 ◽  
Vol 19 (7) ◽  
pp. A585
Author(s):  
S Eljamel ◽  
JS Evans ◽  
A Griffiths ◽  
I Banerjee ◽  
K Hussain ◽  
...  
Keyword(s):  
United Kingdom ◽  
Cost Of Illness ◽  
Congenital Hyperinsulinism ◽  
The United Kingdom ◽  
Illness Study ◽  
Cost Of Illness Study
Sign in / Sign up

Export Citation Format

Share Document